About 1 in 10 people with ANCA-associated vasculitis (AAV) failed to achieve complete remission at three months after starting…
Articles by Margarida Maia, PhD
Argenx is planning to launch a proof-of-concept clinical trial later this year to test its therapy efgartigimod, approved to…
May is Vasculitis Awareness Month and this year there are plenty of ways to get involved and raise awareness…
ANCA-associated vasculitis (AAV) patients undergoing dialysis for kidney failure have a lower risk of relapse, but a higher risk…
People with relapsing ANCA-associated vasculitis (AAV) who achieved remission with rituximab and glucocorticoids have less than half the…
ANCA-associated vasculitis (AAV) patients with proteinuria, elevated protein levels in their urine, after induction treatment are at a three…
People with granulomatosis with polyangiitis (GPA) are more likely to develop an aneurysm — a bulge in a blood vessel…
More than one-third of people with granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis, may experience eye symptoms,…
Higher blood levels of soluble interleukin 7 receptor subunit alpha (sIL-7R alpha) — a portion of a receptor protein involved…
An elderly woman was diagnosed with ANCA-associated vasculitis (AAV) after having an ischemic stroke, a condition wherein a blood…